Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Mehdi Hamadani(Medical College of Wisconsin), Carlos Litovich(Medical College of Wisconsin), Javier Bolaños‐Meade(Johns Hopkins University), Jonathon B. Cohen(Emory University), Rodrigo Martino(Universitat Autònoma de Barcelona), Hemant S. Murthy(University of Florida), Yago Nieto(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Jennifer A. Kanakry(National Institutes of Health), Nasheed Hossain(Loyola University Chicago), Sachiko Seo(National Cancer Center Hospital East), Alberto Mussetti(Duran i Reynals Hospital), Pashna N. Munshi(Johns Hopkins Hospital), Rizwan Romee(Washington University in St. Louis), Baldeep Wirk(Boston University), Nelli Bejanyan(Moffitt Cancer Center), Ephraim J. Fuchs(Johns Hopkins University), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Hisham Abdel‐Azim(University of Southern California), David J. Inwards(Mayo Clinic), Nilanjan Ghosh(Levine Cancer Institute), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Bipin N. Savani(Vanderbilt University Medical Center), Umar Farooq(Wake Forest University), Jean A. Yared(University of Maryland, Baltimore), Ana Sureda(Institut Català d'Oncologia), Kwang Woo Ahn(Medical College of Wisconsin)
Cited by 77
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916